Your browser doesn't support javascript.
Use of Intravenous Vitamin C in Critically Ill Patients With COVID-19 Infection.
Li, Matthew; Ching, Tsung Han; Hipple, Christopher; Lopez, Ricardo; Sahibzada, Asad; Rahman, Habibur.
  • Li M; New York City Health + Hospitals/Queens, Jamaica, NY, USA.
  • Ching TH; New York City Health + Hospitals/Queens, Jamaica, NY, USA.
  • Hipple C; 5925Icahn School of Medicine at Mount Sinai, NY, USA.
  • Lopez R; Independent Researcher.
  • Sahibzada A; New York City Health + Hospitals/Queens, Jamaica, NY, USA.
  • Rahman H; 5925Icahn School of Medicine at Mount Sinai, NY, USA.
J Pharm Pract ; : 8971900211015052, 2021 Jun 08.
Article in English | MEDLINE | ID: covidwho-2232464
ABSTRACT

INTRODUCTION:

The pathophysiology for Coronavirus Disease 2019 (COVID-19) infection is characterized by cytokine oxidative stress and endothelial dysfunction. Intravenous (IV) vitamin C has been utilized as adjuvant therapy in critically ill patients with sepsis for its protective effects against reactive oxygen species and immunomodulatory effects. The primary objective of this study was to evaluate the effects of IV vitamin C in critically ill patients with COVID-19 infection.

METHODS:

Retrospective observational cohort study with propensity score matching of intensive care unit (ICU) patients who received 1.5 grams IV vitamin C every 6 hours for up to 4 days for COVID-19 infection. The primary study outcome was in-hospital mortality. Secondary outcomes included vasopressor requirements in norepinephrine equivalents, ICU length of stay, and change in Sequential Organ Failure Assessment (SOFA) score.

RESULTS:

Eight patients received IV vitamin C and were matched to 24 patients. Patients in the IV vitamin C group had higher rates of hospital mortality [7 (88%) vs. 19 (79%), P = 0.049]. There was no difference in the daily vasopressor requirement in the treatment group or between the 2 groups. The mean SOFA scores post-treatment was higher in the IV vitamin C group (12.4 ± 2.8 vs. 8.1 ± 3.5, P < 0.005). There was no difference in ICU length of stay between the treatment and control groups.

CONCLUSION:

Adjunctive IV vitamin C for the management of COVID-19 infection in critically ill patients may not decrease the incidence of mortality, vasopressor requirements, SOFA scores, or ventilator settings.
Keywords

Full text: Available Collection: International databases Database: MEDLINE Type of study: Cohort study / Experimental Studies / Observational study / Prognostic study / Randomized controlled trials Language: English Journal: J Pharm Pract Journal subject: Pharmacy Year: 2021 Document Type: Article Affiliation country: 08971900211015052

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Type of study: Cohort study / Experimental Studies / Observational study / Prognostic study / Randomized controlled trials Language: English Journal: J Pharm Pract Journal subject: Pharmacy Year: 2021 Document Type: Article Affiliation country: 08971900211015052